Magnetic Nanoplatform With Novel Potential for the Treatment of Bone Pathologies: Drug Loading and Biocompatibility on Blood and Bone Cells

M. G. MONTIEL SCHNEIDER; AZCONA P; CAMPELO, ADRIÁN; MASSHEIMER, VIRGINIA L.; AGOTEGARAY M; LASALLE VERÓNICA

IEEE TRANSACTIONS ON NANOBIOSCIENCE

IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC

Lugar: New York; Año: 2023 vol. 22 p. 11 - 18

1536-1241

—Magnetic iron oxide nanoparticles (MNPs)coated with citric acid (MG@CA) are proposed as raw materials for the treatment of bone diseases. Citric acid (CA) wasselected as coating due to its role in the stabilization ofapatite nanocrystals and as a signaling agent for osteoblastactivation. Raloxifene (Ral), curcumine (Cur) and methyleneblue (MB) were employed as model drugs as therapeuticagents for bone diseases. Characterization of raw and drugloaded nanosystems was conducted in order to elucidatethe mechanisms governing interactions between therapeutics and the magnetic platform. Biocompatibility studieswere performed on red blood cells (RBCs) from peripheralhuman blood. Cytotoxicity was evaluated on endothelialcells (ECs); and viability was studied for bone cells exposedat concentrations of 1, 10 and 100 µg/mL of the magneticnano-platform. MG@CA exhibited proper physicochemicalproperties for the applications intended within this work.It presented satisfactory biocompatibility on peripheral redblood cells. Only doses of 100 µg/mL induced a decreasein metabolic activity of ECs and MC3T3-E1 cells. Drugadsorption efficiency was estimated as 62.0, 15.0 and 54.0% for Ral, Cur and MB and drug loading capability of 12.0,20.0 and 13.6%, respectively.